Contact us
Facebook
Google+
Twitter
LinkedIn

Home
Company
Our platform
- HLA-G platform
- IVS-3001 – anti-HLA-G CAR T cells
Clinical Trials
Resources
- Glossary
- Invectys publications
News
- Press Releases
- Events
Contact
- Contact us
- Careers

Home
Company
Our platform
- HLA-G platform
- IVS-3001 – anti-HLA-G CAR T cells
Clinical Trials
Resources
- Glossary
- Invectys publications
News
- Press Releases
- Events
Contact
- Contact us
- Careers

Home / Fichier média / Invectys Pierre Langlade Demoyen, PDG 2

Invectys Pierre Langlade Demoyen, PDG 2

On the same subject

Founded in 2010 out of the Pasteur Institute, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancer with its headquarters in Houston, Texas and Research & Innovation center in Paris.

Invectys exploits a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two platforms: 1) HLA-G, a powerful immune checkpoint and a tumor specific antigen; 2) the universal tumor antigen telomerase (TERT) that is critical to uncontrolled cell growth.

Menu

Contact us
Legal notices
Press Releases

Contact US

Invectys Inc.
109 North Post Oak Lane,
Suite 600, Houston,
TX 77024, USA

Follow US

Facebook
Google+
Twitter
LinkedIn

Credits

Communication and editorial: Acorelis
Graphic creation and development: 17Pixel.com

Copyright © 2024 Invectys